Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide ...
The FDA has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation system for use as an adjunct therapy in adolescents with major depressive disorder.
The EMA initially rejected Rezurock due to uncertainty over its clinical benefit, noting that the pivotal study had no comparator arm and permitted concomitant therapies.
Jointly released last month in Rotterdam by the American Heart Association and American Academy of Pediatrics, these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback